ACADIA PHARMACEUTICALS Business Summary

ACADIA Pharmaceuticals Inc. (ACAD) is a commercial-stage biopharmaceutical leader specializing in the development and commercialization of therapies for central nervous system (CNS) disorders and rare diseases. The company generates revenue primarily through direct product sales of its two FDA-approved flagship treatments: NUPLAZID (pimavanserin), the first approved therapy for Parkinson’s disease psychosis, and DAYBUE (trofinetide), the first treatment for Rett syndrome. Following a milestone fiscal year in 2025 where total revenues reached $1.08 billion, ACADIA has issued 2026 revenue guidance of $1.22 billion to $1.28 billion, supported by the launch of the DAYBUE STIX formulation and a 30% expansion of its commercial field force. ACADIA competes in the neuropsychiatry and orphan disease markets against firms such as Intra-Cellular Therapies, Neurocrine Biosciences, and Jazz Pharmaceuticals, maintaining a dominant market position through its first-mover advantage in Rett syndrome and a specialized commercial infrastructure targeting high-unmet-need CNS populations. The company is led by Chief Executive Officer Catherine Owen Adams, who joined in September 2024 after serving as Senior Vice President and General Manager at Bristol Myers Squibb, where she managed a $20 billion commercial business. The current executive team includes Mark Schneyer as Executive Vice President and Chief Financial Officer, who previously held senior roles at Pfizer and Lazard, and Dr. Elizabeth H.Z. Thompson as Executive Vice President and Head of Research and Development, leading a pipeline that includes late-stage candidates for Alzheimer’s disease psychosis and Prader-Willi syndrome. ACADIA was founded in 1993 by Dr. Mark Brann and continues to be backed by prominent institutional investors, most notably Baker Bros. Advisors, which maintains significant board representation through Chairman Dr. Stephen Biggar. In March 2026, the company further expanded its board with the appointment of Jonathan M. Poole, signaling a continued focus on strategic financial management and long-term growth.